{"id":9715,"date":"2026-04-08T16:05:41","date_gmt":"2026-04-08T16:05:41","guid":{"rendered":"https:\/\/stoxpo.com\/?p=9715"},"modified":"2026-04-08T16:05:41","modified_gmt":"2026-04-08T16:05:41","slug":"viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/","title":{"rendered":"Viking Therapeutics: A High-Stakes Year in the Obesity Drug Race"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><em>Late-stage pipeline progress and market momentum position the biotech as a key emerging player<\/em><\/h4>\n\n\n\n<p>Viking Therapeutics (VKTX) is entering a pivotal phase in 2026, with investors closely watching its progress in the highly competitive obesity drug market. The clinical-stage biotech company has gained significant attention due to its lead candidate, VK2735, a dual GLP-1 and GIP receptor agonist designed to compete with blockbuster treatments from industry leaders.<\/p>\n\n\n\n<p>The company\u2019s biggest catalyst remains its ongoing Phase 3 clinical trials for VK2735. Enrollment for the VANQUISH-1 study has already been completed ahead of schedule, with more than 4,600 patients enrolled, while the VANQUISH-2 trial is nearing completion. These milestones mark an important step toward potential regulatory approval and commercialization, with key data expected later in 2026.<\/p>\n\n\n\n<p>Earlier-stage results have been encouraging. In Phase 2 trials, VK2735 demonstrated weight loss of up to 14.7% over 13 weeks without a plateau, positioning it as a strong contender in a market projected to exceed $100 billion in the coming years. The company is also advancing both injectable and oral formulations, with the oral version expected to enter Phase 3 trials in the second half of 2026.<\/p>\n\n\n\n<p>Beyond its flagship obesity program, Viking continues to build a broader pipeline targeting metabolic and endocrine disorders, supported by a solid balance sheet and disciplined capital management. This financial strength is critical as the company navigates the high costs associated with late-stage clinical development.<\/p>\n\n\n\n<p>Investor sentiment remains cautiously optimistic. While competition from major pharmaceutical companies like Eli Lilly and Novo Nordisk is intense, Viking\u2019s dual-mechanism approach and rapid trial progress have positioned it as a credible challenger. Additionally, growing industry interest in obesity treatments has fueled speculation around potential partnerships or acquisition opportunities.<\/p>\n\n\n\n<p>As Viking Therapeutics advances toward key clinical readouts, 2026 stands as a defining year. Success in its Phase 3 trials could transform the company from a development-stage biotech into a major player in one of the fastest-growing segments in healthcare.<\/p>\n\n\n\n<p>You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/global-markets-surge-in-relief-rally-as-geopolitical-tensions-ease\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Global Markets Surge in Relief Rally as Geopolitical Tensions Ease<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Late-stage pipeline progress and market momentum position the biotech as a key emerging player Viking Therapeutics (VKTX) is entering a pivotal phase in 2026, with investors closely watching its progress in the highly competitive obesity drug market. The clinical-stage biotech company has gained significant attention due to its lead candidate, VK2735, a dual GLP-1 and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1430,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[]},"categories":[308,361],"tags":[421,416,418,676,417,793],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/9715"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=9715"}],"version-history":[{"count":2,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/9715\/revisions"}],"predecessor-version":[{"id":9717,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/9715\/revisions\/9717"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1430"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=9715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=9715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=9715"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=9715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}